Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bactevo nets deal with Boehringer Ingelheim
June 2018
SHARING OPTIONS:

CAMBRIDGE, U.K.—A drug discovery collaboration was recently announced between Bactevo Ltd. and Boehringer Ingelheim centered on the identification of novel small-molecule lead compounds. Though no specific financial details were released, the multi-program agreement stipulates that Boehringer Ingelheim will make upfront payments as well as providing research funding, and Bactevo will also be eligible for research, development and commercialization milestone payments.
 
“We are pleased to be commencing this highly complementary collaboration with Boehringer Ingelheim,” David Williams, CEO of Bactevo, said in a press release. “It combines our cutting-edge TIME [Totally Integrated Medicines Engine] drug discovery platform with the powerful therapeutic drug development and commercialization experience at Boehringer Ingelheim to create much-needed new medicines in areas outside of our current therapeutic focus.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.